Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre‐enfortumab vedotin era-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre‐enfortumab vedotin era

Published:2022-03-18 Issue:7 Volume:29 Page:647-655
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Kita Yuki¹^ORCID,Ito Katsuhiro¹^ORCID,Sano Tomoyasu²,Hashimoto Kohei³^ORCID,Mochizuki Takanori⁴,Shiraishi Yusuke⁵,Araki Hiromasa⁶,Fujiwara Maki⁷,Kanamaru Sojun⁸,Takahashi Takehiro⁹,Hishiki Kosuke¹⁰,Okada Takuya¹¹,Ogawa Kosuke¹²,Ito Masaaki¹³,Kojima Takahiro¹⁴,Nishiyama Naotaka¹⁵,Matsui Yoshiyuki¹⁶,Nishiyama Hiroyuki¹⁴,Kitamura Hiroshi¹⁵,Kobayashi Takashi¹^ORCID

Affiliation:

1. Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan

2. Department of Urology Nagoya University Nagoya Japan

3. Department of Urology Sapporo Medical University Sapporo Japan

4. Department of Urology University of Yamanashi Hospital Chuo Japan

5. Department of Urology Shizuoka General Hospital Shizuoka Japan

6. Department of Urology National Hospital Organization Kyoto Medical Center Kyoto Japan

7. Department of Urology Tenri Hospital Tenri Japan

8. Department of Urology Kobe City Nishi‐kobe Medical Center Kobe Japan

9. Department of Urology Osaka Red Cross Hospital Osaka Japan

10. Department of Urology Shimada General Medical Center Shimada Japan

11. Department of Urology Tazuke Kofukai, Medical Research Institute Kitano Hospital Osaka Japan

12. Department of Urology Kyoto Katsura Hospital Kyoto Japan

13. Department of Urology Rakuwakai Otowa Hospital Kyoto Japan

14. Department of Urology University of Tsukuba Tsukuba Japan

15. Department of Urology University of Toyama Toyama, Japan

16. Department of Urology National Cancer Center Hospital Tokyo Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14861

Reference12 articles.

1. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

3. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

4. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab

5. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan;International Journal of Urology;2024-03-12

2. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

3. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data;International Journal of Urology;2024-02-25

4. Editorial Comment on Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan;International Journal of Urology;2024-02-17

5. Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan;International Journal of Urology;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3